CCM
TYRA icon

Coldstream Capital Management’s Tyra Biosciences TYRA Stock Holding History

Coldstream Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28
Closed -$260 – 3211
2025
Q1 		$260 Buy
+28
New +$362 ﹤0.01% 3461

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Coldstream Capital Management's TYRA Position: Q2 2025 in Review

Coldstream Capital Management sold out of Tyra Biosciences (TYRA) in Q2 2025, closing a stake of 28 shares — an estimated $260 sold.

Coldstream Capital Management first reported a position in TYRA in Q1 2025 and held it in 1 quarter. The position peaked at $260 in Q1 2025. 121 funds tracked by Wall St. Rank hold TYRA as of Q2 2025.

  • Coldstream Capital Management reported no remaining Tyra Biosciences position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 28 Tyra Biosciences shares in Q2 2025, an estimated $260.
  • Coldstream Capital Management first reported a position in Tyra Biosciences in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Tyra Biosciences position peaked at $260 in Q1 2025.
  • 121 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.